{
    "clinical_study": {
        "@rank": "149660", 
        "arm_group": [
            {
                "arm_group_label": "BC-819/PEI and BCG alternating", 
                "arm_group_type": "Experimental", 
                "description": "4 weekly treatments of BC-819/PEI alternating with BCG"
            }, 
            {
                "arm_group_label": "BC-819/PEI and BCG Vaccine sequential", 
                "arm_group_type": "Experimental", 
                "description": "4 weekly treatments of BC-819/PEI followed by 4 weekly treatments of BCG"
            }, 
            {
                "arm_group_label": "bi-weekly treatments of BC-819 and BCG", 
                "arm_group_type": "Experimental", 
                "description": "6 bi-weekly treatments of BC-819/PEI and BCG"
            }
        ], 
        "brief_summary": {
            "textblock": "-  Safety and tolerability of three regimens of intravesically administered BC-819/PEI and\n           BCG (number of participants with AEs, discontinuations due to AEs)\n\n        -  Recurrence after treatment with BC-819/PEI and BCG\n\n        -  Approximately 18 patients with superficial transitional cell carcinoma TCC) of the\n           bladder\n\n        -  After initial evaluation and qualification, patients will be randomized to one of two\n           treatment groups, either alternating or sequential"
        }, 
        "brief_title": "Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Transitional Cell Carcinoma of Bladder", 
        "condition_browse": {
            "mesh_term": [
                "Urinary Bladder Neoplasms", 
                "Carcinoma", 
                "Carcinoma, Transitional Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with superficial papillary transitional cell carcinoma of the bladder for\n             whom BCG is clinically indicated. If CIS is present, diagnosis needs to be confirmed\n             by biopsy prior to the start of the study.\n\n          2. Males or females more than 18 years old\n\n          3. All papillary tumors must be resected within 8 weeks prior to the start of study\n             therapy.\n\n          4. ECOG performance status 2 or less.\n\n          5. Adequate hematologic function, as demonstrated by\n\n               1. Hemoglobin 10 g/dL or higher\n\n               2. ANC 1.5 x 109/L or higher\n\n               3. Platelets higher than 100 x 109/L\n\n          6. Adequate liver and renal function as demonstrated by\n\n               1. AST and ALT each 3.0 x ULN or less\n\n               2. Total bilirubin 1.5 x ULN or less\n\n               3. Creatinine 1.5 X ULN OR less, creatinine clearance >60 mL/min\n\n          7. If fertile and sexually active, must use adequate contraception\n\n          8. Must be able to comply with protocol requirements, including attendance at required\n             clinic visits.\n\n          9. Patients must provide written informed consent.\n\n             -\n\n        Exclusion Criteria:\n\n          1. Patients who are candidates for either partial or total bladder resection, unless\n             either medically contraindicated or who have refused surgery.\n\n          2. Patients with a tumor in a diverticulum, in the prostatic urethra, or covering the\n             ureteral orifice.\n\n          3. Patients who have received cytotoxic drugs, systemic corticosteroids or any\n             investigational drug for any indication within 4 weeks of the start of protocol\n             treatment.\n\n          4. Patients who have received any intravesical therapy other than surgical resection\n             within 8 weeks prior to the start of protocol treatment.\n\n          5. Patients who have received radiation therapy for bladder cancer at any time or for\n             any condition within 4 months prior to the start of protocol treatment.\n\n          6. Patients who have active infections, including urinary tract infections, whether\n             viral, bacterial or fungal and requiring therapy.\n\n          7. Patients who are receiving coumadin.\n\n          8. Patients who have had to discontinue a past course of BCG due to toxicity.\n\n          9. Patients who are having urinary tract signs or symptoms from recent urinary tract\n             procedures or manipulations, such as biopsies or catheterizations.\n\n         10. Patients who are known to be HIV positive.\n\n         11. Females who are pregnant or breast feeding.\n\n         12. Presence of any medical, psychological or social condition or situation which may, in\n             the investigator's opinion, make it difficult for the patient to tolerate study\n             medication or comply with study procedures and other requirements. This includes but\n             is not limited to active infections, poorly controlled diabetes, uncontrolled cardiac\n             arrhythmias, angina pectoris, or hypertension.\n\n             -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01878188", 
            "org_study_id": "BC-BLAD-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "BC-819/PEI and BCG alternating", 
                    "BC-819/PEI and BCG Vaccine sequential", 
                    "bi-weekly treatments of BC-819 and BCG"
                ], 
                "description": "Intravesical instillation", 
                "intervention_name": "BC-819/PEI", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "BC-819/PEI and BCG alternating", 
                    "BC-819/PEI and BCG Vaccine sequential", 
                    "bi-weekly treatments of BC-819 and BCG"
                ], 
                "description": "intravesical instillations", 
                "intervention_name": "BCG Vaccine", 
                "intervention_type": "Drug", 
                "other_name": "OncoTICE"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "BCG Vaccine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 25, 2014", 
        "link": {
            "url": "http://www.biocancell.com/"
        }, 
        "location": [
            {
                "contact": {
                    "email": "kochi.biton@b-zion.org.il", 
                    "last_name": "Kochava Biton, SN", 
                    "phone": "+97248359542"
                }, 
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel"
                    }, 
                    "name": "Bnai Zion MC"
                }, 
                "investigator": {
                    "last_name": "Sarel Halachmi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jeniti@clalit.org.il", 
                    "last_name": "Yevgenia Tikhominova, SC", 
                    "phone": "+972-54-5973350"
                }, 
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel"
                    }, 
                    "name": "Carmel Medical Center"
                }, 
                "investigator": {
                    "last_name": "Avraham Stein, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ami Sidi, Phd", 
                    "phone": "972-3-5028653"
                }, 
                "facility": {
                    "address": {
                        "city": "Holon", 
                        "country": "Israel"
                    }, 
                    "name": "Wolfson Medical Center"
                }, 
                "investigator": {
                    "last_name": "Ami Sidi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ogofrit@gmail.com", 
                    "last_name": "Ofer Gofrit, MD", 
                    "phone": "+972-2-6776874"
                }, 
                "facility": {
                    "address": {
                        "city": "Jerusalem", 
                        "country": "Israel"
                    }, 
                    "name": "Hadassah Ein Karem Medical Center"
                }, 
                "investigator": {
                    "last_name": "Ofer Gofrit, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "leibovitchi@clalit.org.il", 
                    "last_name": "Ilan Leibovitch, MD", 
                    "phone": "+97297471557"
                }, 
                "facility": {
                    "address": {
                        "city": "Kfar Saba", 
                        "country": "Israel"
                    }, 
                    "name": "Meir MC"
                }, 
                "investigator": {
                    "last_name": "Ilan Leibovitch, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "hmatzkin@tlvmc.gov.il", 
                    "last_name": "Haim Matzkin, MD", 
                    "phone": "+972-3-6973265"
                }, 
                "facility": {
                    "address": {
                        "city": "Tel Aviv", 
                        "country": "Israel"
                    }, 
                    "name": "Tel Aviv Medical Center"
                }, 
                "investigator": {
                    "last_name": "Haim Matzkin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Amnonz@asaf.health.gov.il", 
                    "last_name": "Amnon Zisman, MD", 
                    "phone": "+972-8-9779409"
                }, 
                "facility": {
                    "address": {
                        "city": "Zerifin", 
                        "country": "Israel"
                    }, 
                    "name": "Assaf Harofe Medical Center"
                }, 
                "investigator": {
                    "last_name": "Amnon Zisman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase I Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma", 
        "overall_official": [
            {
                "affiliation": "Wolfson Medical Center", 
                "last_name": "Ami Sidi, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Bnai-Zion Medical Center, Haifa, Israel", 
                "last_name": "Sarel Halachmi, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Meir Medical Center, Kfar-Saba, Israel", 
                "last_name": "Ilan Leibovitch, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hadassah Ein Karem Medical Center", 
                "last_name": "Ofer Gofrit, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Assaf Harofe Medical Center", 
                "last_name": "Amnon Zisman, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Carmel Hospital,Haifa", 
                "last_name": "Abraham Stein, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Tel Aviv Medical Center", 
                "last_name": "Haim Matzkin, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety and tolerability of three regimens of intravesically administered BC-819/PEI and BCG by number of subjects with AEs and change from baseline for clinical safety laboratory tests", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01878188"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Recurrence of bladder cancer after treatment with BC-819/PEI and BCG", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "BioCancell Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioCancell Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}